Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer
Open accessThe DOI matches its Crossref record.
Abstract
Purpose: We compared oral capecitabine, administered intermittently or continuously, versus classical cyclophosphamide, methotrexate, and fluorouracil (CMF) as first-line chemotherapy for women with advanced breast cancer unsuited to more intensive regimens. Patients and Methods: Three hundred twenty-three eligible women were randomly assigned to capecitabine administered intermittently (1,000 mg/m 2 twice daily for 14 of every 21 days; n = 107) or continuously (650 mg/m 2 twice daily for 21 of every 21 days; n = 107), or to classical CMF (oral cyclophosphamide 100 mg/m 2 days 1 to 14 with intravenous methotrexate 40 mg/m 2 and fluorouracil 600 mg/m 2 on days 1 and 8 every 28 days; n = 109). The primary end point was quality-adjusted progression-free survival (PFS); secondary end points included PFS, overall survival (OS), objective tumor response, and adverse events. Intermittent and continuous capecitabine were to be compared first and, if similar (P > .05), combined for definitive comparisons versus CMF. Results: Quality-adjusted PFS (P = .2), objective tumor response rate (20%; P = .8), and PFS (median, 6 months; hazard ratio [HR], 0.86; 95% CI, 0.67 to 1.10; P = .2) were similar in women assigned capecitabine versus CMF. OS was longer in women assigned capecitabine rather than CMF (median, 22 v 18 months; HR, 0.72; 95% CI, 0.55 to 0.94; P = .02). Febrile neutropenia, infection, stomatitis, and serious adverse events were more common with CMF; hand-foot syndrome was more common with capecitabine. Conclusion: Capecitabine improved OS by being similarly active, less toxic, and more tolerable than CMF. Capecitabine is a good first-line chemotherapy option for women with advanced breast cancer who are unsuited to more intensive regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationCardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., Olivo, M. S., He, Y., Dutcus, C. E., & Cortes, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4892 · Cited by 463
Metadata
- Authors
- Stockler, M. R., Harvey, V. J., Francis, P. A., Byrne, M. J., Ackland, S. P., Fitzharris, B., Van Hazel, G., Wilcken, N. R. C., Grimison, P. S., Nowak, A. K., Gainford, M. C., Fong, A., Paksec, L., Sourjina, T., Zannino, D., Gebski, V., Simes, R. J., Forbes, J. F., & Coates, A. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-12-01
- Volume
- 29
- Issue
- 34
- Pages
- 4498-4504
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171611244
- Cited by
- 152
- References
- 0
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2010.33.9101
- The paper
- Stockler, M. R., Harvey, V. J., Francis, P. A., Byrne, M. J., Ackland, S. P., Fitzharris, B., Van Hazel, G., Wilcken, N. R. C., Grimison, P. S., Nowak, A. K., Gainford, M. C., Fong, A., Paksec, L., Sourjina, T., Zannino, D., Gebski, V., Simes, R. J., Forbes, J. F., & Coates, A. S. (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.9101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.